{
    "nctId": "NCT01035099",
    "briefTitle": "RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF",
    "officialTitle": "A Randomized Open Label Clinical Trial of Fixed Dose Letrozole vs. Titrated Letrozole for In Vitro Fertilization With Cryopreservation of Oocytes and Embryos in Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Infertility",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 41,
    "primaryOutcomeMeasure": "Mature Oocyte Yield",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female breast cancer patient with breast cancer diagnosis after surgery and before undergoing chemotherapy desiring fertility preservation with oocyte or embryo cryopreservation\n* Healthy subject according to documented medical history and physical examination who has been diagnosed with breast cancer (estrogen and progesterone receptor positive and/or negative)\n* Age less that 45 years at time of informed consent\n* Verbal or written clearance from medical or surgical oncologist to undergo controlled ovarian hyperstimulation-IVF\n* Delay to chemotherapy treatment will not jeopardize cancer treatment outcome\n* Ovarian stimulation will not affect cancer treatment plan\n* Transvaginal ultrasound scan (US) within one month of starting stimulation with no clinically significant pelvic mass\n* Serum FSH level (Day 2-4) less than 25\n* Negative pregnancy test prior to beginning Letrozole or gonadotropin therapy\n* Willing and able to comply with the protocol\n* Voluntary provision of written informed consent, prior to any study related procedure that was not part of normal medical care, with the understanding that the subject can withdraw consent at any time without prejudice to her future medical care\n* Willingness to provide follow-up information on herself and babies born as part of this study\n\nExclusion Criteria:\n\n* Patients not medically cleared by their oncologist\n* Patients with stage IV breast cancer based on the poor prognosis, general health of the patient, and higher uncertainty with delaying chemotherapy\n* Any clinically relevant abnormal laboratory value (FSH \\>25 miu/ml, renal function, (greater than two times normal value), hepatic function (greater than two times normal value), blood biochemistry, hematology (elevated white blood count greater than 1.5 times the normal value, hemoglobin \\<10mg/dL, thrombocytopenia), abnormal cholesterol profile (total cholesterol \u2265 300mg/dL, abnormal LDL greater than 2 times normal value,) based on a fasting sample during the screening phase\n* Contraindications for the use of gonadotropins (i.e. Tumors other than breast cancer, pregnancy, lactation, undiagnosed vaginal bleeding)\n* Recent or current medical conditions where the patient is not medically stable to undergo stimulation or egg retrieval, HIV infection, diabetes, cardiovascular disease, gastrointestinal, hepatic disease, undiagnosed pelvic mass, renal or pulmonary disease\n* History or presence of alcohol or drug abuse within 12 months of signing consent\n* History of severe allergic or anaphylactic reactions or hypersensitivity to any of the concomitant medication prescribed as part of the treatment regimen in this protocol\n* Administration of investigational drugs within three months prior to signing the informed consent\n* Use of insulin sensitizing agents at least one month prior to signing informed consent\n* Any patient who is not a candidate for IVF",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT"
}